A DOUBLE BLIND COMPARATIVE STUDY ON THE EFFICACY OF S6472, CEFACLOR IN THE TREATMENT OF BACTERIAL BRONCHITIS

• Published in: Japanese journal of antibiotics Vol. 39; no. 10; pp. 2726 - 2753
• Main Authors: OSHIMA, SHINICHI, KIKUIRI, TSUYOSHI, NISHIHARA, HISASHI, SHIMIZU, Tatsunori, KURIHARA, YOSHIO, ITOH, CHOEI, TAKEUCHI, KEISUKE, YAJIMA, OSAMU, TANGO, MIKIHIKO, ODAGAKI, EINOSUKE, ICHISHIMA, YOSHIAKI, ISHIKAWA, KIYOFUMI, SUZUKI, AKIRA, ASAGAWA, MITSUO, NAKAMURA, MITSUNARI, HIRAGA, YOMEI, KIKUCHI, KOHKI, YAMAMOTO, ASAKO, NAKAYAMA, ICHIROH, TOMISAWA, MASUMI, HIRAYAMA, AKIO, UEHARA, SOICHIRO, OYAMA, YOHTAROH, SEKINE, KYUICHIRO, NATSUISAKA, TOHRU, NAKABAYASHI, TAKEHITO, SAITOH, TAKAHISA, KOROKU, TETSUSHI, KON, HIROSHI, NAKAZATO, TAKASHI, KIRISAWA, TOSHIO, TAKAGI, HIROSHI, SUZUKI, KATSUO, SATOH, MIKIYA, NAGAHAMA, FUMIO, KURODA, RENSUKE, KONDO, FUMIEI, GOCHO, YOICHI, NASUHARA, KOICHI, TAKAHORI, TAKASHI, UJIIE, AKIRA, SHINOHARA, MASAHIDE, FUKUHARA, IKUO, OHHASHI, RYOHJI, ONODERA, SOKICHI, SHIMIZU, TETSUO, SASAKI, NOBUHIRO, IKEDA, YUJI, ISHII, YOSHIRO, TOSAKA, MATSUMI, WATANABE, HAJIME, SHIBAKI, HIDETOSHI, CHIMOTO, TAKEHISA, SUGAWARA, YOSHITAKA, TAKEBE, KAZUO, OKAMOTO, KATSUHIRO, YOSHIDA, SYUICHIRO, NAKAMURA, TERUO, KUMASAKA, YOSHIHIRO, MIYAZAWA, TADASHI, YONEDA, MASASHI, MASAKI, NAOYOSHI, KURAHASHI, KOHZO, HIROTA, NORIHIKO, TAMURA, MASAO, ITOH, TAKASHI, MORI, SHIGEKI, YAMAUCHI, FUMITOSHI, OMURO, KIYOSHI, ISHIKAWA, YUTAKA, TSURUYA, TAKASHI, KURAMITSU, HIROSHI, GOMI, KAZUTOSHI, MORIYA, KATSUYOSHI, MATSUI, MIKIO, MAIYA, NORIMI, SATOH, MASAO, NEMOTO, YOSHIKATSU, KAWAMORITA, KIYOSHI, YAOI, HIROYOSHI, ITAZAWA, MASAAKI, SHINDOH, SABURO, FURUTA, MAMORU, KAISHIO, KIICHI, SATOH, KAZUO, KONNO, KIYOSHI, AONUMA, SEIICHI, OHNUMA, KIKUO, HONDA, TOKUJI, ARIJI, FUMIO, YOSHIDA, ICHIRO, WAKASA, KAZUO, NISHINA, MORIAKI, SAEKI, RYOSUKE, HASUIKE, TERUO, ITO, TSUGUSHI, TAKIZAWA, SHIGEO, MATSUMOTO, YUZURU, KOHSAKA, SHIGEMI, SHIKANAI, KENKICHI
• Format: Journal Article
• Language: Japanese
• Published: Japan Japan Antibiotics Research Association 01.10.1986
• Subjects: Adult; Aged; Bacterial Infections - drug therapy; Bronchitis - drug therapy; Bronchitis - microbiology; Cefaclor - pharmacology; Cefaclor - therapeutic use; Cephalexin - analogs & derivatives; Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; Female; Gram-Negative Bacteria - drug effects; Gram-Positive Bacteria - drug effects; Humans; Male; Middle Aged
• ISSN: 0368-2781; 2186-5477
• DOI: 10.11553/antibiotics1968b.39.2726

Clinical efficacy and safety of S 6472 (long active cefaclor (CCL)) and CCL were compared by a double-blind study using 248 patients with bacterial bronchitis. Patients were orally administered with either 375mg of S 6472 2 times or 250mg of CCL 3 times daily for 7 days, and the following results were obtained. 1. Clinical efficacy judged by a committee: The efficacy rates on acute bronchitis were 87.2% for S 6472 and 82.6% for CCL, and the efficacy rates on chronic bronchitis were 70.3% for S 6472 and 64.7% for CCL. There was no significant difference between the 2 drugs in clinical efficacy. 2. Clinical efficacy judged by doctors in charge: Results of the clinical efficacy judged by doctors in charge were similar to the efficacy judged by the committee. 3. Bacteriological efficacy judged by the committee: Eradication rate for the S 6472 group was 71.1% (32 of 45 patients) and that for the CCL group was 67.4% (29 of 43 patients). There was no significant difference between the 2 drugs in the bacteriological efficacy. 4. Side effects and abnormal laboratory findings: Side effects were observed in 5 cases (4.2%) in the S 6472 group and in 5 cases (4.0%) in the CCL group. These side effects, however, were not serious, and no remarkable abnomal laboratory values were observed. There was no significant difference between the 2 drugs in the incidence of side effects or abnormal laboratory findings. 5. Clinical utility: When the clinical utility was expressed by the utility rate (very useful and useful), it was 79.5% in the S 6472 group (117 patients) and 76.2% in the CCL group (122 patients)(judged by the committee). When the utility was judged by doctors in charge, it was 73.3% in S 6472 group (120 patients) and 71.4% in CCL group (126 patients). From the above results, it has been concluded that S 6472 taken twice daily is equivalent to CCL in effectiveness on bacterial bronchitis.